The Utility of ODM-201 in CRPC
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, on the utility of the androgen receptor inhibitor ODM-201 for the treatment of castration-resistant prostate cancer (CRPC).
Clinical Pearls
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, on the utility of the androgen receptor inhibitor ODM-201 for the treatment of castration-resistant prostate cancer (CRPC).
- In phase I and II multinational trials, favorable results have been observed regarding PSA kinetics modulation
- The organic structure of ODM-201 seems to cause the agent to have a much lower penetration through the blood-brain barrier
- The efficacy of ODM-201 is being measured in terms of its impact on radiographic disease, PSA, and the androgen receptor
- ODM-201 has been studied in patients prior to and following chemotherapy, as well as in patients who have and have not received abiraterone
- Additional trials are being planned to analyze safety, efficacy, and tolerability
- ODM-201 will be studied in a large trial of non-metastatic patients
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
